FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1897113776> ?p ?o ?g. }

• W1897113776 endingPage "2300" @default.
• W1897113776 startingPage "2293" @default.
• W1897113776 abstract "To determine the maximum-tolerated dose (MTD) and the dose-limiting toxicities (DLTs) of the raltitrexed plus oxaliplatin combination regimen, to explore its safety and pharmacokinetics, and to assess its antitumor activity in patients with advanced solid tumors.Forty-eight patients received the combination of raltitrexed plus oxaliplatin. Raltitrexed was administered as a 15-minute infusion followed by oxaliplatin as a 2-hour infusion 1 hour later, repeated every 3 weeks. Seven dose levels were explored, ranging from 2 to 3.75 mg/m(2) and from 85 to 130 mg/m(2) for raltitrexed and oxaliplatin, respectively. The pharmacokinetics of both raltitrexed and oxaliplatin was assessed at the last three dose levels.Forty-six patients were assessable for toxicity. Severe toxicities usually occurred from dose level V (raltitrexed 3 mg/m(2) and oxaliplatin 130 mg/m(2)). This combination was not myelosuppressive, eliciting only sporadic grades 3 and 4 neutropenia and/or thrombocytopenia without complications. There was no alopecia. DLTs were asthenia and nausea/vomiting, despite systematic antiemetic prophylaxis. Dose level VI (raltitrexed 3.5 mg/m(2) and oxaliplatin 130 mg/m(2)) was deemed to be the MTD. Eight confirmed partial responses were observed: six patients with malignant mesothelioma (both pretreated and nonpretreated), one with fluorouracil-refractory pancreatic carcinoma, and one with renal carcinoma. Evaluation of the pharmacokinetics of both drugs did not suggest any drug interaction.The combination of raltitrexed and oxaliplatin given as consecutive short infusions every 3 weeks seems to be an acceptable regimen that allows a dose-intensity as high as the sum of the recommended doses of each agent given alone. The dose recommended for further phase II studies is raltitrexed 3 mg/m(2) and oxaliplatin 130 mg/m(2) every 3 weeks. Promising antitumor activity has been observed in patients with malignant mesothelioma." @default.
• W1897113776 created "2016-06-24" @default.
• W1897113776 creator A5002480455 @default.
• W1897113776 creator A5007779528 @default.
• W1897113776 creator A5016732780 @default.
• W1897113776 creator A5021624793 @default.
• W1897113776 creator A5028039056 @default.
• W1897113776 creator A5035737598 @default.
• W1897113776 creator A5047771337 @default.
• W1897113776 creator A5060254160 @default.
• W1897113776 creator A5082689339 @default.
• W1897113776 creator A5085121407 @default.
• W1897113776 creator A5090236257 @default.
• W1897113776 date "2000-06-11" @default.
• W1897113776 modified "2023-10-18" @default.
• W1897113776 title "Phase I, Dose-Finding, and Pharmacokinetic Study of Raltitrexed Combined With Oxaliplatin in Patients With Advanced Cancer" @default.
• W1897113776 cites W1873275656 @default.
• W1897113776 cites W1973405779 @default.
• W1897113776 cites W1982522230 @default.
• W1897113776 cites W1988323129 @default.
• W1897113776 cites W1999531425 @default.
• W1897113776 cites W2014463413 @default.
• W1897113776 cites W2027279621 @default.
• W1897113776 cites W2034081467 @default.
• W1897113776 cites W2045239954 @default.
• W1897113776 cites W2051667118 @default.
• W1897113776 cites W2106482770 @default.
• W1897113776 cites W2110519215 @default.
• W1897113776 cites W2119270435 @default.
• W1897113776 cites W2122731269 @default.
• W1897113776 cites W2147271502 @default.
• W1897113776 cites W2152486489 @default.
• W1897113776 cites W2167805334 @default.
• W1897113776 doi "https://doi.org/10.1200/jco.2000.18.11.2293" @default.
• W1897113776 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10829050" @default.
• W1897113776 hasPublicationYear "2000" @default.
• W1897113776 type Work @default.
• W1897113776 sameAs 1897113776 @default.
• W1897113776 citedByCount "64" @default.
• W1897113776 countsByYear W18971137762012 @default.
• W1897113776 countsByYear W18971137762013 @default.
• W1897113776 countsByYear W18971137762014 @default.
• W1897113776 countsByYear W18971137762015 @default.
• W1897113776 countsByYear W18971137762016 @default.
• W1897113776 countsByYear W18971137762017 @default.
• W1897113776 crossrefType "journal-article" @default.
• W1897113776 hasAuthorship W1897113776A5002480455 @default.
• W1897113776 hasAuthorship W1897113776A5007779528 @default.
• W1897113776 hasAuthorship W1897113776A5016732780 @default.
• W1897113776 hasAuthorship W1897113776A5021624793 @default.
• W1897113776 hasAuthorship W1897113776A5028039056 @default.
• W1897113776 hasAuthorship W1897113776A5035737598 @default.
• W1897113776 hasAuthorship W1897113776A5047771337 @default.
• W1897113776 hasAuthorship W1897113776A5060254160 @default.
• W1897113776 hasAuthorship W1897113776A5082689339 @default.
• W1897113776 hasAuthorship W1897113776A5085121407 @default.
• W1897113776 hasAuthorship W1897113776A5090236257 @default.
• W1897113776 hasConcept C112705442 @default.
• W1897113776 hasConcept C121608353 @default.
• W1897113776 hasConcept C126322002 @default.
• W1897113776 hasConcept C2776694085 @default.
• W1897113776 hasConcept C2777063308 @default.
• W1897113776 hasConcept C2779268555 @default.
• W1897113776 hasConcept C2780580376 @default.
• W1897113776 hasConcept C2780852908 @default.
• W1897113776 hasConcept C2780884295 @default.
• W1897113776 hasConcept C2780962732 @default.
• W1897113776 hasConcept C2781413609 @default.
• W1897113776 hasConcept C526805850 @default.
• W1897113776 hasConcept C71924100 @default.
• W1897113776 hasConcept C90924648 @default.
• W1897113776 hasConcept C98274493 @default.
• W1897113776 hasConceptScore W1897113776C112705442 @default.
• W1897113776 hasConceptScore W1897113776C121608353 @default.
• W1897113776 hasConceptScore W1897113776C126322002 @default.
• W1897113776 hasConceptScore W1897113776C2776694085 @default.
• W1897113776 hasConceptScore W1897113776C2777063308 @default.
• W1897113776 hasConceptScore W1897113776C2779268555 @default.
• W1897113776 hasConceptScore W1897113776C2780580376 @default.
• W1897113776 hasConceptScore W1897113776C2780852908 @default.
• W1897113776 hasConceptScore W1897113776C2780884295 @default.
• W1897113776 hasConceptScore W1897113776C2780962732 @default.
• W1897113776 hasConceptScore W1897113776C2781413609 @default.
• W1897113776 hasConceptScore W1897113776C526805850 @default.
• W1897113776 hasConceptScore W1897113776C71924100 @default.
• W1897113776 hasConceptScore W1897113776C90924648 @default.
• W1897113776 hasConceptScore W1897113776C98274493 @default.
• W1897113776 hasIssue "11" @default.
• W1897113776 hasLocation W18971137761 @default.
• W1897113776 hasLocation W18971137762 @default.
• W1897113776 hasOpenAccess W1897113776 @default.
• W1897113776 hasPrimaryLocation W18971137761 @default.
• W1897113776 hasRelatedWork W2003697710 @default.
• W1897113776 hasRelatedWork W2033327063 @default.
• W1897113776 hasRelatedWork W2049464048 @default.
• W1897113776 hasRelatedWork W2080135046 @default.
• W1897113776 hasRelatedWork W2328289339 @default.
• W1897113776 hasRelatedWork W2473512607 @default.

• next